What are examples of NNRTI?

12/12/2020 Off By admin

What are examples of NNRTI?

What are the FDA-approved NNRTIs and their side effects?

  • Delavirdine (Rescriptor)
  • Efavirenz (Sustiva)
  • Etravirine (Intelence)
  • Nevirapine (Viramune, Viramune XR)
  • Rilpivirine (Edurant)
  • Doravirine (Pifeltro)

What is NNRTI resistance?

NNRTIs bind to a hydrophobic pocket of HIV-1 reverse transcriptase (RT), the viral enzyme that conducts reverse transcription of the viral RNA genome into DNA. HIV-2 is intrinsically resistant to most NNRTIs [1].

Is nevirapine a NNRTI?

Nevirapine is a highly specific inhibitor of HIV-1 reverse transcriptase (RT), an important therapeutic target for the treatment of HIV infection. It was the first non-nucleoside RT inhibitor (NNRTI) to be approved for use in HIV-infected individuals, including children.

Is delavirdine a NNRTI?

The four FDA-approved NNRTIs are nevirapine, delavirdine, efavirenz, and etravirine, and several compounds are in clinical development.

Which is non-nucleoside inhibitors?

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and block HIV reverse transcriptase (an HIV enzyme). HIV uses reverse transcriptase to convert its RNA into DNA (reverse transcription). Blocking reverse transcriptase and reverse transcription prevents HIV from replicating.

Is Dolutegravir an NNRTI?

High rates of non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance was a key consideration in the WHO policies transitioning first-line regimens to include integrase inhibitors (dolutegravir [DTG]).

What are the side effects of tenofovir?

Tenofovir may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • diarrhea.
  • headache.
  • depression.
  • rash.
  • itching.
  • fever.
  • difficulty falling asleep or staying asleep.
  • gas.

What is the brand name for delavirdine?

Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate.